Vaxart, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
Vaxart, Inc. (VXRT) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings of $3 for the 3-month period ending 2019-03-31, per its 10-Q filed 2019-05-09.
Discontinued › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings · last filed 2021-02-25
- Vaxart, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2019-03-31 was $3.00, a 99.90% decline year-over-year.
- Vaxart, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2018-12-31 was $0.00.
- Vaxart, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2018-09-30 was $0.00.
- Vaxart, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2018-06-30 was $0.00.
- Vaxart, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2018 was $3.00K.
- Vaxart, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2017 was -$3.35M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month |
|---|---|---|---|---|
| 2019-03-31 | $3.00 10-Q · filed 2019-05-09 | $3.00 derived: sum of 2 quarters · filed 2021-02-25 | $3.00 derived: sum of 3 quarters · filed 2021-02-25 | $3.00 derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $0.00 derived: sum of 2 quarters · filed 2021-02-25 | $0.00 derived: sum of 3 quarters · filed 2021-02-25 | $3.00K 10-K · filed 2021-02-25 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $0.00 derived: sum of 2 quarters · filed 2019-11-12 | $3.00K 10-Q · filed 2019-11-12 | -$2.38M derived: sum of 4 quarters · filed 2019-11-12 |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $3.00K 10-Q · filed 2019-08-08 | -$2.38M derived: sum of 3 quarters · filed 2019-08-08 | -$2.84M derived: sum of 4 quarters · filed 2019-08-08 |
| 2018-03-31 | $3.00K 10-Q · filed 2018-05-15 | -$2.38M derived: sum of 2 quarters · filed 2019-02-06 | -$2.84M derived: sum of 3 quarters · filed 2019-02-06 | -$3.16M derived: sum of 4 quarters · filed 2019-02-06 |
| 2017-12-31 | -$2.38M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-06 | -$2.85M derived: sum of 2 quarters · filed 2019-02-06 | -$3.17M derived: sum of 3 quarters · filed 2019-02-06 | -$3.35M 10-K · filed 2019-02-06 |
| 2017-09-30 | -$464.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | -$784.00K derived: sum of 2 quarters · filed 2018-11-13 | -$966.00K 10-Q · filed 2018-11-13 | |
| 2017-06-30 | -$320.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-10 | -$502.00K 10-Q · filed 2018-08-10 | ||
| 2017-03-31 | -$182.00K 10-Q · filed 2018-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B |